Italian Study Shows Up to 90% Efficacy at 12 Months in Stage T2b and T3 High Risk Patients

EDAP TMS S.A. to Present at the Roth Capital 2007 Orange County Conference Lyon, France, February 16, 2006 - EDAP TMS S.A. (Nasdaq: EDAP) , the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production, and

EDAP TMS S.A. to Release 2006 Year End Financial Results Lyon, France, March 5, 2007 - EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production, and distribution of a wide

Ablatherm-HIFU Tours to Accelerate HIFU Adoption for Prostate Cancer, Add New Users and Sites EDAP Marketing Programs Driving Patient Inquiries, Moving Doctors to Action

Clear Global Leader in Prostate Cancer HIFU Continues Market Acceleration Strengthening Its Position by Adding New RPP Sites

EDAP Leverages Expertise in Distributing Innovative Urinary Systems

Europe's RPP Program: On Track to Group Profitability The USA: EDAP's New and Exciting Opportunity

Mobile RPP Utilization Increasing, New Centers Added; Strong Commitment from Distribution Partne

Distributor Meeting, User Group Sessions, Media Conferences to Highlight Ablatherm-HIFU

Six-City Tour Generates Awareness, Training Demand for Ablatherm-HIFU TherapyEAU Congress Interest Advances German Market Growth